Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P
Divisions of Senology, European Institute of Oncology, Milan, Italy.
Lancet. 2002 Mar 30;359(9312):1122-4. doi: 10.1016/S0140-6736(02)08159-X.
Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.
他莫昔芬是预防乳腺癌的候选药物，尽管试验结果并不一致。在我们对意大利他莫昔芬试验的延长随访（中位时间81.2个月，四分位间距66.0 - 87.2）中，该药物对患乳腺癌风险正常或略低的女性并无显著的预防作用（p = 0.215）。使用激素替代疗法会增加患乳腺癌的风险，随机分配接受他莫昔芬治疗的此类使用者的乳腺癌发病率与从未使用者相近。到目前为止，该研究中尚无女性死于乳腺癌。关于引入他莫昔芬以降低乳腺癌风险的决策仍然是重要且有待解决的问题。
